Mazen Elyan, MD
Rheumatology · Crestview Hills, KYNPI 1104978048
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.7%), consulting fees and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Fresenius Kabi USA, LLC at 36.9% of the total. Reporting peaked in 2023 at $1,760 and has fallen 70.2% since, to $524 in 2025.
Across 103 payments — averaging $37.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius Kabi USA, LLC$1K
- AbbVie$581
- Amgen$515
- GSK$225
- Novartis$177
- Boehringer Ingelheim$139
- plus $779 from 15 others
What the payments were for
- Consulting fees$1,85548%
- Food & beverage$1,94151%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius Kabi USA, LLC | 2 | $1,415 |
| AbbVie | 29 | $581 |
| Amgen(2 entities) | 16 | $515 |
| GSK | 5 | $225 |
| Novartis | 10 | $177 |
| Boehringer Ingelheim | 2 | $139 |
| Johnson & Johnson | 6 | $109 |
| Cardinal Health 110 LLC | 1 | $100 |
| UCB, Inc. | 4 | $84 |
| E.r. Squibb & Sons, L.L.C. | 5 | $80 |
| Pfizer | 5 | $74 |
| Mallinckrodt Hospital Products Inc. | 2 | $67 |
| Lilly USA, LLC | 5 | $67 |
| AstraZeneca(2 entities) | 3 | $54 |
| Radius Health, Inc. | 2 | $27 |
| Sanofi | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Octapharma USA, Inc. | 1 | $16 |
| Sandoz | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,832 in reported general payments places this provider in the 60th percentile of 81 rheumatology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 59 | $393,453 |
| Cosentyx Sensoready PenSecukinumab | 33 | $222,626 |
| Enbrel SureclickEtanercept | 19 | $162,716 |
| Xeljanz XrTofacitinib Citrate | 16 | $134,010 |
| Actemra ActpenTocilizumab | 31 | $121,188 |
| RinvoqUpadacitinib | 18 | $114,586 |
| Taltz AutoinjectorIxekizumab | 13 | $88,306 |
| SimponiGolimumab | 11 | $67,467 |
| Teriparatide | 14 | $46,379 |
| Leflunomide | 114 | $8,479 |
| MethotrexateMethotrexate Sodium | 210 | $5,938 |
| Hydroxychloroquine Sulfate | 163 | $4,542 |
| Cevimeline Hcl | 17 | $2,376 |
| Mycophenolate Mofetil | 20 | $2,322 |
| Celecoxib | 48 | $2,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $581 | $114,58618 claims |
| Johnson & JohnsonSimponi | $109 | $67,46711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 81 rheumatology providers in Kentucky.
Other rheumatology in Crestview Hills
- Liza VargheseCrestview Hills$29K
- Christopher ColglazierCrestview Hills$22K
- Kerrin BurteCrestview Hills$16K
- Abraham TacangCrestview Hills$9K
- Ann GeorgeCrestview Hills$8K
- Magdalena WiniarskaCrestview Hills$5K
- Sarah KellerCrestview Hills$3K
- Joseph TemmingCrestview Hills$2K
- Nicola JacksonCrestview Hills$2K
- Zehra KazmiCrestview Hills$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.